Navigation Links
MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy
Date:8/15/2011

TUCSON, Ariz., Aug. 15, 2011 /PRNewswire-USNewswire/ -- More than a decade of targeted Muscular Dystrophy Association-funded research, made possible as a result of generous public support of the MDA Labor Day Telethon and thousands of grass-roots special events, has today culminated in MDA providing financial assistance for the start of the first Phase 2 placebo-controlled, multiple dose efficacy, safety, tolerability and pharmacokinetics clinical trial of an exon-51 skipping drug, eteplirsen, as a potential therapy for Duchenne muscular dystrophy (DMD).

The first three of 12 DMD boys participating in the AVI BioPharma clinical trial at Nationwide Children's Hospital in Columbus, Ohio today received the first of 24 weekly doses of eteplirsen or a placebo by intravenous infusion (i.v.).  Four more participants had muscle biopsies vital to measuring the presence of the essential muscle protein dystrophin both before and after treatments.  The seven boys traveling in for the study launch are from Calif., Ill., Fla., Wis., Va. and Mo.

"This is an important day for families fighting muscular dystrophy," said R. Rodney Howell, M.D., Chairman of the MDA Board of Directors. "AVI BioPharma already completed a 19-patient clinical trial in the United Kingdom confirming the potential of eteplirsen to be a safe and effective disease-modifying drug for DMD (The Lancet, July 25, 2011).  Now, a team led by Dr. Jerry Mendell is receiving funding from MDA to help initiate this randomized, double-blind, placebo-controlled 12-patient trial needed to further test safety, efficacy and optimal dosing."

"Twenty-five years ago, MDA-funded investigators identified the dystrophin gene that, when mutated (or defective) causes Duchenne muscular dystrophy as well as the somewhat milder Becker muscular dystrophy (BMD)," explained Mendell, Curran-Peters Chair of Pediatric Research at Nationwide Children's Hospital, and Professor of Pediatrics and Neurology at Ohio State University. "Today, we're underway with a clinical trial of a drug that ultimately could create a shortened but functional dystrophin protein for DMD boys with certain out-of-frame gene deletions that may be corrected by skipping exon 51."

"By administering eteplirsen by i.v. for 24 weeks," Mendell added, "our goal is to find the best dosage to trick the body into skipping over genetic disruptions present in some cases of DMD, to produce dystrophin levels typical of Becker muscular dystrophy.  In Becker many patients are able to walk into late adulthood and to have normal or near normal life spans."

The introduction of exon skipping to restore the open reading frame using splice-switching oligomers targeting dystrophin exons is one of several attractive therapeutic strategies for Duchenne muscular dystrophy being pioneered by MDA-funded investigators.  

"MDA has been funding exon skipping research for Duchenne muscular dystrophy for more than a decade," noted Valerie Cwik, M.D., MDA Executive Vice President – Research and Medical Director.  "We're very pleased to now be collaborating with AVI BioPharma on this trial and are hopeful that eteplirsen will become an effective therapy for those living with Duchenne muscular dystrophy."

About MDA

MDA is the nonprofit health agency dedicated to curing muscular dystrophy, ALS and related diseases by funding worldwide research.  The Association also provides comprehensive healthcare and support services, advocacy and education.  

In addition to funding more than 300 research teams worldwide, MDA maintains a national network of some 200 hospital-affiliated clinics; orchestrates hundreds of support groups for families affected by neuromuscular diseases; and facilitates extraordinary local summer camp opportunities for thousands of youngsters fighting progressive muscle diseases.  The Association is the first nonprofit to receive a Lifetime Achievement Award from the American Medical Association "for significant and lasting contributions to the health and welfare of humanity."  

The Association's unparalleled programs are funded almost entirely by generous public contributions to the MDA Labor Day Telethon and by other grass roots fund-raising events orchestrated by MDA year-round.  The 2011 Telethon will be broadcast nationwide by more than 150 television stations on Sunday, Sept. 4, between 6:00 p.m. and midnight in every time zone.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. By leveraging a highly differentiated RNA-based technology platform, AVI has built a pipeline of potentially transformative therapeutic agents, including a clinical stage Duchenne muscular dystrophy candidate and anti-infective candidates for influenza and hemorrhagic fever viruses.  AVI targets a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike siRNA, and other RNA-based approaches, AVI technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins.

About Nationwide Children's Hospital

As one of the largest and most comprehensive pediatric hospitals and research institutes in the United States, Nationwide Children's is a resource and an advocate for children and parents in central Ohio and far beyond. In fact, in a typical year, Nationwide Children's sees patients from across the country and around the world. The Research Institute at Nationwide Children's Hospital is one of the nation's 10 largest free-standing pediatric research centers and works to enhance the health of children by engaging in high-quality, cutting-edge research. The work carried out every day is dedicated to improving the health of children and their families in Central Ohio and beyond.


'/>"/>
SOURCE Muscular Dystrophy Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaNet Collaborates With the Cancer Immunotherapy Trials Network
2. CoreLab Partners Collaborates at Worldwide Industry Conferences
3. Cepheid Collaborates With Pharmaceutical Leader on Chronic Myelogenous Leukemia
4. Brainlab Collaborates With Toshiba Medical Systems on Integrated Surgical Suite
5. SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise
6. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
7. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
8. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
9. Comparative Study Confirms Enox Biopharmas Antimicrobial Superiority to Commercially Available Silver Coated Catheters
10. Biopharma Leaders Discuss Pharmas Future at Pharmaceutical Strategic Alliances in New York
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their ... Eyeglasses . , Millions of individuals in the United States and Canada wear eyeglasses. ... way to both correct vision and make a fashion statement. Even celebrities use glasses ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
Breaking Medicine News(10 mins):